title: Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
abstract: The avian H5N1 influenza virus has the potential to cause a new pandemic. The increasing number of recent outbreaks of highly pathogenic avian influenza H5N1 in birds and humans emphasizes the urgent need to develop a potent H5N1 vaccine. Here, we studied the immunogenicity and protective effect of a vaccine prepared from H5N1 inactivated whole virus. This vaccine was intranasally co-administered in mice with phosphate buffered saline, recombinant cholera toxin B subunit (rCTB), cholera toxin (CT), rCTB containing a trace amount of holotoxin (rCTB/CT), polyinosinic:polycytidylic acid double-stranded RNA (polyI:C), or MF59 as an adjuvant. Intranasal administration of H5N1 inactivated whole virus vaccine with rCTB, CT, rCTB/CT, polyI:C, and MF59 elicited an immunological response with both secretory IgA (sIgA) in nasal, lung, and vaginal lavage, and IgG antibody in serum, showing protective immunity against lethal H5N1 infection. Cross-clade protection was also observed in animals immunized with a vaccine derived from Anhui/01/2005(H5N1) with rCTB, CT, rCTB/CT, polyI:C, or MF59 as adjuvants that were subsequently challenged with the A/OT/SZ/097/03 influenza strain.
authors.affiliation: Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, 20 Dong-Da Street, Fengtai District, Beijing 100071, China.
authors.forename: Penghui
authors.initials: P
authors.lastname: Yang
authors.forename: Chong
authors.initials: C
authors.lastname: Tang
authors.forename: Deyan
authors.initials: D
authors.lastname: Luo
authors.forename: Zhongpeng
authors.initials: Z
authors.lastname: Zhan
authors.forename: Li
authors.initials: L
authors.lastname: Xing
authors.forename: Yueqiang
authors.initials: Y
authors.lastname: Duan
authors.forename: Weihong
authors.initials: W
authors.lastname: Jia
authors.forename: Daxin
authors.initials: D
authors.lastname: Peng
authors.forename: Xiufan
authors.initials: X
authors.lastname: Liu
authors.forename: Xiliang
authors.initials: X
authors.lastname: Wang
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000281:Administration, Intranasal; D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006385:Hemagglutination Inhibition Tests; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D009976:Orthomyxoviridae Infections / Q000276:immunology* / Q000821:virology; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology; D019562:Viral Load
chemical_list: D000276:Adjuvants, Immunologic; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic